Tunisia - fransk - Ministère de la Santé, Direction de l'inspection Pharmaceutique

viiv healthcare uk limited - zidovudine - gélule - 100 mg - antiinfectieux generaux a usage systemique - antiviraux (usage systemique) - retrovir gélule est indiqué dans le cadre d'associations antirétrovirales, pour le traitement de l'adulte et de l'enfant infectés par le virus de l'immunodéficience humaine (vih). la chimioprophylaxie par retrovir est indiquée chez la femme enceinte, séropositive pour le vih (après 14 semaines d'aménorrhée), dans la prévention de la transmission materno-fotale du vih et dans la prophylaxie primaire de l'infection par le vih chez le nouveau-né.

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

janssen-cilag (new zealand) ltd - bedaquiline fumarate 120.89mg equivalent to bedaquiline 100 mg;  ;   - tablet - 100 mg - active: bedaquiline fumarate 120.89mg equivalent to bedaquiline 100 mg     excipient: colloidal silicon dioxide croscarmellose sodium hypromellose lactose monohydrate magnesium stearate maize starch microcrystalline cellulose polysorbate 20 - sirturo is indicated in adult (greater than or equal to 18 years) and pediatric patients (12 years to less than 18 years of age and weighing at least 30 kg) as part of combination therapy of pulmonary tuberculosis (tb) due to multi-drug resistant mycobacterium tuberculosis.

Malaysia - engelsk - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

johnson & johnson sdn. bhd. - bedaquiline fumarate -

Spania - spansk - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

laboratorios viiv healthcare - zidovudina - excipientes: - antivirales de acciÓn directa - nucleosidos y nucleotidos inhibidores de la transcriptasa inversa - zidovudina

Spania - spansk - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

laboratorios viiv healthcare s.l. - zidovudina - soluciÓn oral - 10 mg/ml - zidovudina 10 mg - zidovudina

Spania - spansk - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

laboratorios viiv healthcare s.l. - zidovudina - cÁpsula dura - 250 mg - zidovudina 250 mg - zidovudina

Sveits - tysk - Swissmedic (Swiss Agency for Therapeutic Products)

abbvie ag - ritonavirum - sirup - ritonavirum 600 mg, aromatica, saccharinum natricum, color.: e 110, excipiens ad solutionem pro 7.5 ml corresp. ethanolum 43.2 % v/v. - hiv-infektionen - synthetika human

Irland - engelsk - HPRA (Health Products Regulatory Authority)

viiv healthcare uk ltd - zidovudine - capsules hard - 100 milligram - nucleoside and nucleotide reverse transcriptase inhibitors

Irland - engelsk - HPRA (Health Products Regulatory Authority)

viiv healthcare uk ltd - zidovudine - oral solution - 100 mg/10ml - nucleoside and nucleotide reverse transcriptase inhibitors

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - rifampicin, quantity: 150 mg - capsule - excipient ingredients: maize starch; magnesium stearate; gelatin; erythrosine; titanium dioxide; indigo carmine - tuberculosis. in the initial treatment and in re-treatment of patients with tuberculosis, rifadin must be used in conjunction with at least one other antituberculosis drug. leprosy. in the management of lepromatous leprosy and dimorphous leprosy to effect speedy conversion of the infectious state to the noninfectious state, which may be expected to occur in 3 to 4 months of treatment. as an alterantive drug in lepromatous, dimorphous, indeterminate and tuberculoid leprosy resistant to sulfones and other antileprosy drugs. as an alternative drug in all those patients having true drug allergy to the more commonly used antileprosy drugs. meningococcal disease. prophylaxis of meningococcal disease in close contacts of known cases and in carriers. (rifadin is not indicated for the treatment of meningococcal infections). haemophilus influenzae. prophylaxis of household contacts of patients with h. influenzae type b.